Michael Bolle appointed designated Chairman of Carl Zeiss Supervisory Board

The Carl Zeiss AG shareholders’ meeting has appointed Dr. Michael Bolle the new Supervisory Board member to represent the sole shareholder the Carl Zeiss Foundation. He will be elected Chairman of the Supervisory Board of Carl Zeiss AG in January 2022. Dr. Bolle will succeed Dr. Dieter Kurz, whose mandate as Chairman of the Supervisory Board of Carl Zeiss AG will end on 31 December 2021 after almost ten years. Effective 1 January 2022, Dr. Bolle will also take over from Dr. Kurz as Chairman of the Shareholder Council of the Carl Zeiss Foundation and will represent all the shareholder interests of the Foundation.

Dr. Dieter Kurz

Since 2012 Dr. Kurz has held the positions of Chairman of the Shareholder Council of the Carl Zeiss Foundation and Chairman of the Supervisory Board of Carl Zeiss AG. He joined ZEISS back in 1979 and from 2001 served as spokesman and President and CEO of ZEISS. “We would like to sincerely thank Dieter Kurz for his decades of commitment to ZEISS and for the exceptional and successful collaboration in his role as Chairman of the Supervisory Board. We wish him all the very best going forward,” said Dr. Karl Lamprecht, President and CEO of Carl Zeiss AG.

 

Dr. Michael Bolle (Foto: Carl-Zeiss-Stiftung / Jan Potente)

Dr. Bolle has a PhD in engineering and has held executive positions at Bosch since 1992 – taking a break from 1999 through 2002 to establish a high-tech startup. Most recently he was Member of the Management Board of Robert Bosch GmbH, Chief Technology Officer (CTO) and Chief Digital Officer (CDO). During his time at Bosch, Dr. Bolle was the driving force behind the creation of the Bosch Center for Artificial Intelligence and helped to link up the Internet of Things with artificial intelligence (AIoT).

“We look forward to working with Dr. Bolle. His high level of skill and vast experience in matters related to the global economy, particularly in the area of digitalization, have equipped him to face the challenges that lie ahead,” said Dr. Lamprecht.